Concepedia

Yumiko Wada

YW

25

Publications

1.5K

Citations

16

H-Index

1983

Active since

Affiliations

Synta Pharmaceuticals (United States)(Current)

University of Tsukuba

Pennsylvania State University

Harvard University

Osaka Medical and Pharmaceutical University

Yumiko Wada is an author at Synta Pharmaceuticals (United States) specializing in medicine, pharmacology, and tumor biology.

Top concepts

MedicinePharmacologyCell BiologyTumor BiologyOncologyDrug DiscoveryCancer ResearchSystems BiologyRadiation OncologyCell Death

Publications per year

1983–2023

25

Publications

25

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells

Masazumi Nagai, Nha Huu Vo, Luisa Shin Ogawa et al. · Free Radical Biology and Medicine · 2012 · 330 citations

Mitochondrial Function, Biochemistry, Medicine +10

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Weiwen Ying, Zhenjian Du, Lijun Sun et al. · Molecular Cancer Therapeutics · 2011 · 227 citations

Cancer Therapy, Ganetespib Exhibits Potent, Pharmacotherapy +19

Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol

Ronald K. Blackman, Kahlin Cheung-Ong, Marinella Gebbia et al. · PLoS ONE · 2012 · 131 citations · Full text

Apoptosis, Cell Death, Redox Biology +21

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

Jaime Acquaviva, Donald L. Smith, Jim Sang et al. · Molecular Cancer Therapeutics · 2012 · 98 citations

Tumor Biology, Radiation Oncology, Low-dose Ganetespib +15

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor

Yumiko Wada, Rongzhen Lu, Dan Zhou et al. · Blood · 2006 · 88 citations · Full text

Rows per page

1–5 of 25